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trend. Low HDL cholesterol (HDL-C) and elevated triglyc-
eride levels are attributed as the two key contributors to the 
high residual CHD risk (2). Therefore, in the last decade, 
an increased focus has been on elevating the plasma con-
centration of HDL-C as a generally accepted intervention 
to prevent or reduce the development of CHD (3, 4), as 
opposed to the lowering of high LDL cholesterol (LDL-C), 
which in turn accelerates the fat accumulation into arterial 
walls. Traditionally, a high HDL-C concentration in blood 
has been regarded as a preventive measure reflecting the 
ability of HDL particles to transport CHOL from the pe-
ripheral tissues back to the liver, including the mainly LDL-
derived CHOL from the arterial walls. This process is 
termed reverse CHOL transport (RCT) (5, 6). However, 
there is a growing body of literature showing that the ele-
vation of the HDL-C by niacin or cholesterol ester (CE) 
transfer protein inhibitors does not, or only moderately 
improves cardiovascular events (7–9). In addition, recent 
genetic association studies have raised doubts toward the 
HDL-C hypothesis and causality of HDL-C in the develop-
ment of CHD (9–11). The failure of a large number of 
HDL-C-raising therapies and the findings of genetic studies 
have led to a significant uncertainty concerning the benefit 
of raising HDL-C levels in the treatment of CHD. Still, sev-
eral epidemiological studies support an inverse correlation 
between HDL-C and CHD (9, 12, 13). Hence, the in-depth 
understanding of the structure-function relationship of 
HDL particles and the enzymes processing them at the mo-
lecular level is all the more important for treating CHD.
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Coronary heart disease (CHD) and its comorbidities are 
global health threats showing an increased prevalence in 
industrial as well as in developing countries. Although 
many drugs for treating CHD exist, such as the cholesterol 
(CHOL)-lowering statins, a substantial residual vascular 
risk remains (1). According to the Residual Risk Reduction 
Initiative, this represents a paramount public health chal-
lenge in the twenty-first century (1). Thus, more effective 
medical strategies are needed to slow down and reverse this 
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LCAT (EC 2.3.1.43) is one of the key enzymes driving 
the maturation of nascent HDL particles in serum (14). 
Specifically, LCAT is responsible for linking the acyl chain 
cleaved from a phospholipid (PL) to an unesterified cho-
lesterol (UC) molecule resulting in a CE molecule, which 
in turn transforms discoidal HDL particles to spherical 
ones, which is a crucial step in RCT (15, 16). Essentially, 
the esterification of UC molecules increases the CHOL 
loading capacity of HDL particles, enabling a more effi-
cient RCT. In addition to its importance in RCT, mutations 
in the LCAT gene result in metabolic disorders, such as fa-
milial LCAT deficiency and fish-eye disease in which the 
body’s ability to metabolize CHOL is severed, leading to 
corneal lipid deposition, hemolytic anemia, and finally re-
nal failure (17–19). However, despite the fact that LCAT 
deficiencies are associated with low HDL-C and esterified 
CHOL levels, the role LCAT deficiency in the development 
of atherosclerosis is unclear (20).
The initial step in the reaction cycle of LCAT is its bind-
ing to a lipoprotein surface. Previous research studies have 
established that apolipoproteins, especially the principal 
LCAT activator, apoA-I, play a negligible role in the attach-
ment rate of LCAT to lipoprotein surfaces, but decrease its 
detachment rate from surfaces (21, 22). This suggests that 
LCAT initially binds to the lipid moiety of lipoprotein par-
ticles, which is then followed by interactions with apoA-I 
promoting stronger binding and activation. However, the 
specific amino acids responsible for initially anchoring 
LCAT to lipoprotein surfaces have not been revealed, al-
though deletion mutant studies have shown that amino 
acids 53-71 and the disulphide bond formed between cyste-
ines 50 and 74 of LCAT are crucial for the interfacial 
recognition of LCAT (22–24). Furthermore, it was shown 
by Murray et al. (25) that when LCAT was bound to HDL or 
hydrophobic surfaces during sink immunoassays, the epit-
opes of the 121-136 region were not accessible for antibod-
ies. Moreover, it is not known how deep the LCAT is buried 
into the lipid matrix, whether a membrane binding region 
has specific interactions with different lipids that could fa-
cilitate its activity, and how LCAT is oriented with respect to 
lipoprotein surfaces when bound and not bound to apoA-I. 
The next steps in the reaction cycle are the apoA-I driven 
activation of LCAT by an unknown mechanism and the dif-
fusion of PLs and UC to the active site (14, 26). Conse-
quently, the sn-2 chain of PLs is preferentially lipolyzed and 
the acyl-intermediate of LCAT is formed in which the acyl 
chain is covalently bound to SER181, which is a part of the 
ASP-HIS-SER catalytic triad also found in other lipases be-
longing to the / hydrolase family (14, 27–29). Next, the 
acyl chain bound to SER181 is transferred to UC. Finally, 
the newly synthesized CE molecule diffuses from the active 
site into the lipoprotein. While the LCAT activator region 
of apoA-I (central helixes 5, 6, and 7, or residues 121-142, 
143-164, and 165-186, respectively) is roughly known based 
on the apoA-I LCAT deficiency mutations and a vast amount 
of experimental data, the more specific LCAT interaction 
site and role of this in the different reaction steps remains 
unclear (26, 30, 31). By revealing the mechanisms behind 
the different reaction steps of LCAT, the way may be paved 
for inventing novel positive allosteric modulators of LCAT 
that aim to raise HDL-C in a manner that would be benefi-
cial for the treatment of CHD.
For years, investigations concerning the LCAT lipid bilayer 
interaction and activation by apoA-I have been hindered by a 
lack of the detailed atomistic structure of LCAT. Recently, 
however, X-ray structures of LCAT have become available en-
abling, for example, the computational studies of LCAT in-
teracting with lipid surfaces and apoA-I to elucidate the 
mechanistic details concerning the CHOL esterification pro-
cess (32–35). From the structures it is evident that the tertiary 
and secondary structure of LCAT is similar to lysosomal phos-
pholipase A2, as pointed out by three similar folds: the cap 
domain, the membrane-binding domain, and the / hy-
drolase domain (see Fig. 1A) (35). Most importantly, struc-
tural details reveal that LCAT possesses a lid-loop that can 
move aside from the tunnel opening enabling the entry of 
lipids into the active site where the catalytic triad is located, 
thus being consistent with other lipases (32, 34).
In this study, we carried out several atomistic and coarse-
grained (CG) molecular dynamics simulations to investi-
gate the effects of different conformational states of LCAT 
to its interaction with a lipid bilayer comprised of dio-
leoylphosphatidylcholines (DOPCs) and UC molecules. 
To gain insights into apoA-I-mediated LCAT activation, 
we utilized quartz-crystal-microbalance (QCM) and multi-
parametric surface plasmon resonance (MP-SPR) experi-
ments to investigate the effect of apoA-I-derived peptides 
on the binding of LCAT to lipid bilayers, and the binding 
of LCAT to these peptides, respectively. These experiments 
were complemented with extensive free-energy simulations 
to reveal the role of the secondary structure of apoA-I- 
derived peptides in lipid interactions. Finally, we studied 
the energetics of lipid ligand entry to the active site of LCAT.
Our simulations highlight the importance of specific 
nonpolar amino acids in LCAT-lipid interactions. In addi-
tion, we show that the membrane-anchoring nonpolar 
amino acids attract UC molecules adjacent to them. The 
results also demonstrate that the lid-loop plays an impor-
tant role in the conformation of LCAT with respect to the 
lipid surface. Furthermore, the experiments indicate that 
peptides derived from the LCAT-activating region of apoA-I 
bind differently to LCAT and promote its lipid surface 
binding, although some of the peptides do not bind to lip-
ids individually. We provide an explanation for this mecha-
nism utilizing computational free-energy calculations. It 
was also found that the transfer free-energy of PL from the 
lipid bilayer to the active site is consistent with the activa-
tion energy of LCAT. Finally, our results indicate that the 
acyl-intermediate of LCAT highly facilitates the accessibil-
ity of UC molecules into the active site.
MATERIALS AND METHODS
Computational procedures
Construction of simulation systems. The high-resolution X-ray 
structures of LCAT were acquired from the Brookhaven databank 
 at Terkko - N
ational Library of Health Sciences, on April 27, 2018
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2018/02/23/jlr.M082685.DC1
Supplemental Material can be found at:
672 Journal of Lipid Research Volume 59, 2018
with the accession codes of 4XWG and 5BV7 (32, 34). In addition, 
one mutated residue (C31Y in 4XWG) was changed back to one 
matching with the native LCAT utilizing the PYMOL software 
(36). The 4XWG structure is considered to be the closed confor-
mation and the 5BV7 structure the open conformation of LCAT 
based on the lid-loop orientation with respect to the active site tun-
nel opening. The MODELLER program was utilized to construct 
the missing lid-loop regions in both structures (37). The model 
building script (model-single.py) of the MODELLER program was 
utilized to construct the missing lid-loop regions and 10 different 
lid-loop structures were generated for the open and closed states. 
The structures with the lowest DOPE score were chosen in both 
cases for further modeling studies. It is noteworthy that the resi-
dues 1-20 (N terminal) and 398-422 (C terminal) are totally or 
partially missing from the X-ray structures. These amino acids 
were not added to the structure because their configuration and 
structure, with respect to the rest of the LCAT structure, is highly 
unclear and requires further experimental information. How-
ever, a very recent study indicates that the N- and C-terminal ends 
of LCAT play an important role in LCAT HDL surface interac-
tion. This matter is discussed in the Discussion section in more 
detail.
Two LCAT-in-water systems were constructed: one for the open 
and one for the closed lid-loop conformation. In the rest of the 
article, we refer to these systems by abbreviations LCAT-water-
open and LCAT-water-closed. The dimensions of LCAT-water-
open and LCAT-water-closed simulation boxes were 8.5 × 7 × 
7 nm. The open and closed LCAT enzymes were solvated with 
12,000 water molecules. In addition, nine sodium ions were added 
to neutralize the simulation systems. In the construction of LCAT-
lipid bilayer systems, we used a preequilibrated DOPC/UC bi-
layer available in the website of the Slipid developers. To construct 
atomistic lipid membrane systems, the LCAT was placed on the 
surface of the DOPC/UC bilayer so that the nonpolar residues 
of the tunnel-opening and the membrane binding domain were 
buried in the lipid matrix and the active site tunnel opening 
was pointing toward the lipid bilayer. This was done for both the 
lid-open and lid-closed LCAT structures. The DOPC and UC mol-
ecules overlapping with LCAT were removed from the systems. 
Following this, the systems were solvated approximately with 
20,000 water molecules and nine sodium ions were added to 
neutralize the systems. One additional atomistic system was con-
structed for the open LCAT lid-loop conformation where SER181 
was acylated with an oleic acid. We refer to these all-atom (AA) 
lipid membrane models as LCAT-mem-open-AA, LCAT-mem-
closed-AA, and LCAT-mem-acyl-AA. The starting structures for 
the corresponding CG LCAT-lipid systems representing these 
three atom-scale models were constructed similarly (LCAT-mem-
open-CG, LCAT-mem-closed-CG, and LCAT-mem-acyl-CG). In 
Table 1, a more detailed list of molecules in each simulation sys-
tem is presented.
Simulation force fields and parameters. Molecular dynamics simu-
lations were carried out with the GROMACS simulations package 
(version 5.1.2) (38, 39). The SLipids (http://www.fos.su.se/~sasha/ 
SLipids/) and AMBER99SB-ILDN force fields were utilized for 
lipids and protein molecules in atomistic simulations, respectively 
(40–42). The MARTINI force field was used for the CG represen-
tations (43, 44). The polarizable water and protein models of the 
MARTINI force field were utilized (45, 46).
Concerning the atomistic simulations, all systems were first en-
ergy minimized with the steepest descent algorithm. After this, 
short 10 ns equilibrium simulations were carried out to stabilize 
pressure fluctuations that were followed by 400 ns (LCAT-water 
systems) or 1 s production simulations (LCAT-mem systems). 
The time step was set to 2 fs, and the temperature and pressure 
were maintained at 310 K and 1 bar, respectively. The Berendsen 
coupling schemes were utilized for achieving constant tempera-
ture and pressure during the short equilibrium period of atomistic 
systems (47). After this, the Nose-Hoover and the Parrinello-Rahman 
coupling algorithms were employed for treating temperature and 
pressure in the atomistic systems, respectively (48, 49). The isotro-
pic or semi-isotropic pressure coupling scheme was used in the 
LCAT-water and LCAT-mem systems, respectively. Water plus 
ions, lipids, and protein were separately coupled to heat paths. 
For the Lennard-Jones interactions, a cut-off of 1 nm was used, 
and the electrostatic interactions were handled with the particle-
mesh Ewald method with a real space cut-off of 1.0 (50). The 
LINCS algorithm was applied to constrain covalent hydrogen 
bond lengths (51).
Regarding the CG simulations, the temperature and pressure 
were handled with the v-rescale and the Parrinello-Rahman 
schemes, respectively (49, 52). Coupling constants of 1 and 
12 ps1 were used for the temperature and pressure schemes, re-
spectively. Lipids, protein, and water molecules were separately 
coupled to a heat path. The reaction-field electrostatics and 
Lennard-Jones interactions were employed with cut-offs of 1.1 nm. 
TABLE 1. Simulated systems with their molecular compositions and simulation times
System Details DOPC/POPC CHOL Water (mol/beads)
Total Simulation 
Time (s)
LCAT-water-open-AA Lid open 0 0 12,000 0.4
LCAT-water-closed-AA Lid closed 0 0 12,000 0.4
LCAT-mem-open-AA Lid open 286 132 20,000 1
LCAT-mem-closed-AA Lid closed 286 132 20,000 1
LCAT-mem-acyl-AA SER181 acylated 286 132 20,000 1
LCAT-mem-open-CG Lid open 226 105 10,000 20a
LCAT-mem-closed-CG Lid closed 226 105 10,000 20a
LCAT-mem-acyl-CG SER181 acylated 226 105 10,000 20a
LCAT-mem-open-AA-DOPC-PMF Lid open 286 132 20,000 1.6
LCAT-mem-open-AA-UC-PMF Lid open 286 132 20,000 2.0
LCAT-mem-acyl-AA-UC-PMF SER181 acylated 286 132 20,000 1.7
LCAT-mem-open-CG-LCAT-PMF Lid open 226 105 10,000 96a
LCAT-mem-closed-CG-LCAT-PMF Lid closed 226 105 10,000 96a
Pep_122-142-CG-PMF Helix or coil 128 0 1,800 8a
Pep_135-155-CG-PMF Helix or coil 128 0 1,800 8a
Pep_150-170-CG-PMF Helix or coil 128 0 1,800 8a
Pep_185-205-CG-PMF Helix or coil 128 0 1,800 8a
Pep_150-170-CG-PMF-Y166F Helix or coil 128 0 1,800 8a
a The total simulation time of the CG systems was multiplied by four because the diffusion dynamics of MARTINI 
water beads is approximately four times faster compared with real water (43, 45).
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The relative electrostatic screening was set to 2.5 because the po-
larizable water and protein models of the MARTINI force field 
were used. A time step of 20 fs was used and all CG simulations 
were simulated up to 20 us (scaled MARTINI time). The ElNeDyn 
scheme was employed for LCAT (53).
Free-energy calculations. For calculating the free-energy profiles 
for phosphatidylcholine (PC) or UC molecules entering the ac-
tive site of LCAT, either a UC or a PC molecule was pulled from 
the lipid bilayer to the active site of LCAT in the lid-open state to 
generate umbrella windows (these systems are coined as LCAT-
mem-open-DOPC-PMF-AA and LCAT-mem-open-CHOL-PMF-
AA). The free-energy profiles for PC and UC molecules were 
calculated utilizing atomistic simulations. In addition, the free-
energy profile for a UC molecule was calculated in the LCAT-mem 
systems where SER181 was acylated (LCAT-mem-acyl-UC -PMF-
AA). The oxygen atom of UC or the phosphorous atom of DOPC 
was pulled toward the center of mass of the SER181 residue with 
a pull rate of 0.001 nm/ps and a force constant of 10,000 kJ/mol-
nm2. The resulting reaction coordinate was divided into 39 um-
brella windows. The force-constant of the spring was set to 2,000 
kJ/mol·nm2. Each umbrella window was sampled up to 40–50 ns, 
thus the total simulation time ranged from 1.6 to 2.0 s per sys-
tem. The last 34–28 ns of the simulation trajectories were used to 
construct the PMF profiles.
For determining the lipid-binding free-energies for different 
apoA-I-derived peptides at the CG level, each peptide was pulled 
from the water phase to the center of the POPC bilayer with a pull 
rate of 0.001 nm/ps and a force-constant of 20,000 kJ/mol·nm2. 
This was followed by a generation of 20 umbrella windows along 
the bilayer normal. Each window was sampled up to 100 ns (400 ns 
in scaled MARTINI time) and the centers of mass of peptides 
were constrained to the center of each umbrella window by using 
a force constant of 500 kJ/mol·nm2. The last 320 ns of the simulation 
trajectories were used to construct the PMF profiles. To estimate 
the effect of secondary structure to the binding of free-energies, 
potential mean force (PMF) profiles were calculated for peptides 
fully adopting -helical or coil secondary structures.
In addition to the above systems, the free-energy profiles for 
LCAT along the lipid membrane normal were also estimated. 
First, LCAT was pulled from the surface of DOPC-CHOL mem-
brane to the water phase by using a constant pulling speed of 
0.0002 nm/ps and a force constant of 20,000 kJ/mol·nm2. The 
pulling was done for end structures of LCAT-mem-open-CG and 
LCAT-mem-closed-CG simulations. Next, the reaction coordinate 
was divided into 30 different umbrella windows. Each window was 
sampled up to 0.8 s (3.2 s in scaled MARTINI time) in with a 
force constant of 1,000 kJ/mol·nm2. Thus, the total simulation 
time for each LCAT system was 96 s (scaled MARTINI time). 
The last 2 s of the simulation trajectories were used in the con-
struction of the PMF profiles.
Analysis methods. All the analysis programs reported here are 
part of the GROMACS simulations package unless mentioned 
otherwise. The gmx rmsf and gmx rmsd programs were used to 
produce root-mean-square fluctuation (RMSF) and root-mean-
square deviation (RMSD) graphs. Only the backbone atoms of 
LCAT were included in the RMSD and RMSF analysis. The RMSF 
profiles were calculated as a function of amino acid residues of 
LCAT after the RMSD profiles were stabilized (after 100 ns). The 
secondary structure of LCAT was monitored as a function of time 
with the secondary structure plugin of the VMD (54). The average 
number of hydrogen bonds was calculated utilizing the gmx 
hbond analysis tool. The maximum distance between a donor and 
an acceptor was set to 0.35 nm, and the maximum angle formed 
by hydrogen bonding atoms hydrogen-donor-acceptor was set to 
30 degrees. The number of salt bridges in the structure of LCAT 
concerning the lid-region was calculated by the gmx mindist 
program with a distance criterion of 0.6 nm between the charged 
side chain central carbon atoms of negatively and positively 
charged amino acids (GLU-ARG, GLU-LYS, ASP-ARG, and ASP-
LYS). The solvent-accessible surface areas (SASAs) for the se-
lected amino acids were calculated using the gmx sasa program. 
The distance and tilt analysis were carried out with the gmx mind-
ist and gmx gangle programs. These analyses were conducted af-
ter the number of contacts between protein and head group 
atoms of DOPC were in equilibrium. For producing 2D-spatial 
density maps, the gmx densmap program was used. The XY-planes 
of simulation systems were divided into 100 × 100 or 36 × 36 
square bins, in which the number of UC atoms was calculated in 
each time frame and summed over the whole simulation time to 
produce number density profiles. Before the calculation, the 
membrane puncturing region of LCAT (the center of mass of 
residue PHE67) was placed to the center of the simulation box. 
The gmx_wham program was utilized to derive the PMF profiles 
from the umbrella sampling simulations. The bootstrapping 
method with 50 bins was used to estimate the errors for the PMF 
profiles. All visualizations in this work were made with either the 
Python codes or the VMD visualization package (54).
Experimental procedures
Materials. POPC dissolved in chloroform (25 mg/ml) was ob-
tained from Avanti Polar Lipids (Alabaster, AL). Calcium chloride, 
HEPES, CHAPS, sodium chloride, EDTA, sodium azide, and potas-
sium dihydrogen phosphate were obtained from Merck Sigma- 
Aldrich (Darmstadt, Germany). Potassium chloride was obtained 
from Honeywell Riedel de Haën (Seelz, Germany); disodium hy-
drogen phosphate was obtained from Fisher Scientific (Hampton, 
NH). Peptides and N-terminal biotin-labeled peptides were synthe-
sized by Peptide Protein Research Ltd., Hampshire, UK and had 
the following amino acid sequences: i) 122-142, LRAELQEGAR-
QKLHELQEKLS; ii) 135-155, HELQEKLSPLGEEMRDRARAH; 
iii) 150-170, DRARAHVDALRTHLAPYSDEL; iv) 150-170-Y166F, 
DRARAHVDALRTHLAPFSDEL; and v) 185-205, GGARLAEY-
HAKATEHLSTLSE. Lyophilized glycosylated human LCAT pro-
tein (Sino Biological Inc., Beijing, China; a recombinant protein 
produced in human cells) was reconstituted with 400 l of ultra-
pure sterile water to yield LCAT at 5 M in PBS (manufacturer 
specifications). Ultrapure water used for preparation of the buffer 
and in all measurements was prepared with a Milli-Q purification 
system, having a resistivity of 18 M·cm and TOC level of <5 ppm. 
The following buffers were used: 20 mM PBS, 1 mM EDTA, 1 mM 
Na azide (pH 7.4) (buffer A); and 20 mM HEPES and 150 mM 
NaCl (pH 7.4) (buffer B).
The MP-SPR measurements. Measurements were performed 
with a multi-parameter SPR Navi™ 200 (BioNavis Ltd., Tampere, 
Finland) instrument. The setup was equipped with two incident 
laser wavelengths, 670 nm and 785 nm, two independent flow 
channels, inlet tubing and outlet (waste) tubing, and an autosam-
pler. Both of the flow channels were measured simultaneously 
with 670 nm and 785 nm incident light. The measurement tem-
perature was kept constant at 293° K. Biotin-coated SPR sensors 
(Bionavis Ltd.) were placed in the flow-cell. The flow rates used 
for the streptavidin interaction with biotin, biotin-peptides with 
streptavidin, and for LCAT interaction with immobilized peptides 
were 10 l/min. SPR spectra were recorded after introduction of 
buffer A into the flow-cell for 10–30 min until a stable baseline was 
achieved, after which the surface was fully saturated with streptavi-
din during a 10 min serial injection at 1.9 M to saturate the SPR 
sensor. It was observed that after 5 min the SPR sensor was fully 
coated with streptavidin; therefore, the method was adapted to 5 min. 
In the second phase of the measurement, in DMSO solubilized 
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biotin-peptides with a final concentration of 100 M were in-
jected in parallel into both flow channels for 7 min at 10 M to 
cover the SPR sensor fully, i.e., until all streptavidin bindings sites 
were fully occupied. Parallel injections ensured that two peptides 
were analyzed simultaneously. Increasing concentrations of 
LCAT were then injected into both channels via serial injection, 
to ensure the lowest variation of LCAT injection for 15 min at in-
creasing concentrations (156, 313, 625, 1250, 2,500, and 5,000 nM) 
to determine the binding constant of the LCAT-peptide com-
plexes. The data was fitted in OriginPro (v. 8.6, OriginLab Corp., 
Northampton, MA) according to the Langmuir model to obtain 
the dissociation constants (Kd) and the responses of saturated 
binding (Rmax):
=
+1 /
max
d
R
R
K c
where R is the final response after each injection and c is the con-
centration of LCAT in each injection.
The QCM measurements. Prior to the QCM measurements, the 
PBS buffer formed after reconstitution of LCAT was exchanged 
for buffer A due to the extremely high sensitivity of the QCM 
method to slight differences in the ionic strength of the back-
ground buffer. The LCAT solution was placed in an Amicon 
Ultra-0.5 10K centrifugal filter device (Merck Millipore Ltd., Tul-
lagreen Carrigtohill, Ireland) and equal volumes of buffer A were 
filtered through 10 times at 14,000 g, after which 400 l of buffer 
A were added to fully recover LCAT at 5 M. The peptides were 
dissolved into buffer A at a final concentration of 100 M.
An impedance-based QCM instrument (KSV Instruments Ltd., 
Helsinki, Finland) was used for the measurements. The measure-
ment temperature was kept constant at 293° K. Before measure-
ments, silica-coated QCM sensors (Q-Sense Inc./BiolinScientific, 
Västra Frölunda, Sweden) were first flushed with 70% ethanol 
and ultrapure water, dried under nitrogen flow, and finally oxy-
gen plasma treated (PDC-002; Harrick Plasma, Ithaca, NY) for 
5 min at 29.6 W and 133–173 Pa. Samples were injected into the 
measurement chamber with a peristaltic pump system (Ismatec/
Cole-Parmer GmbH, Wertheim, Germany). Small unilamellar 
POPC liposome vesicles, which were used to form supported lipid 
bilayers (SLBs) inside the QCM measurement chamber, were 
made using the thin-film hydration method followed by extrusion 
(11 times) through a 50 nm polycarbonate filter membrane at 
333° K. The resulting small unilamellar vesicles (10 mg/ml in buf-
fer B) had a mean number average particle size of 65 ± 7 nm and 
a polydispersity index of 0.167 ± 0.008 (determined from three 
individual measurements by a Zetasizer APS instrument; Malvern 
Instruments Ltd., Worcestershire, UK).
After the baseline of the signal at different frequency overtones 
(3, 5, and 7) was stabilized with buffer B, SLBs were formed by 
flowing liposome solution (0.15 mg/ml in buffer B + 5 mM CaCl2 
at 250 l/min) over the crystal surface for 5 min. Afterwards, buf-
fer A was injected and the signal was left to stabilize. An additional 
injection of ultrapure water was added to ensure the complete 
formation of an SLB and absence of intact vesicles on the mea-
surement surface. The overlap of the changes in normalized over-
tone frequencies (26 Hz) was considered to be a confirmation 
of the presence of a good-quality SLB. The flow speed was re-
duced to 50 l/min and the measurements were performed by 
injecting peptides at 100 M in buffer A, LCAT at 37.5 nM in 
buffer A, or a combination of LCAT and peptide, through the 
measurement chamber for a duration of 10 min. Between each 
measurement, sensors were cleaned in situ by sequential 2 min 
injections of 20 mM CHAPS, 2% Hellmanex, 70% ethanol, and 
ultrapure water.
Data analysis was performed using Origin Pro (v. 8.6, Origin-
Lab Corp., Northampton, MA). For each measurement, frequency 
overtone signals (3, 5, and 7) were normalized, averaged, and 
baseline corrected. Neither LCAT nor peptides induced changes 
in viscoelastic properties of the bilayer, which was seen as negligi-
ble changes in the recorded energy dissipation.
RESULTS
The flexible lid-loop covers nonpolar amino acids located 
at the tunnel opening of LCAT from water in the closed 
state
To explore the structural and dynamic properties of the 
lid-loop region of LCAT, we carried out molecular dynam-
ics simulations for LCAT in the lid-open and lid-closed 
states in water (Fig. 1A). In this fashion, we strived to estab-
lish mechanistic insights to the conformational switching 
Fig. 1. A: Structures of LCAT in the lid-open (left) and -closed (right) states rendered as cartoon models. The cap domain is colored with 
purple, the / hydrolase domain with orange, and the membrane-binding domain with red. The tunnel opening of the active site is marked 
with a dashed black sphere. The catalytic triad residues: SER181, ASP345, and HIS377 are rendered with sticks and colored according to ele-
ment types. Cyan atoms are carbon, blue nitrogen, white hydrogen, and red oxygen atoms. B: RSMF profiles for the lid-open and -closed 
states. RMSD results are shown in the inset. C: Secondary structure profiles for the lid-open and -closed states.
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of the lid-loop that, presumably, is a prerequisite for the 
esterification reaction of LCAT to take place. Moreover, 
the overall stability of the LCAT structure was assessed 
against the X-ray structures to validate our computational 
models (32–34). To construct applicable LCAT models for 
these purposes, the lid-loop region (amino acids 233-247) 
was computationally grafted to the high resolution X-ray 
structures of LCAT representing either the open or closed 
state (32, 34). During this work, another high-resolution 
X-ray structure of LCAT was published (Protein Data Bank 
accession code: 5TXF) in the lid-closed conformation with 
only two amino acid residues missing from the lid-loop re-
gion (33). This provided us an excellent means to validate 
our grafted LCAT model in the closed state. As shown in 
supplemental Fig. S1, our model is in good agreement with 
the published LCAT structure in the closed state. The pro-
duced LCAT models were simulated up to 400 ns in water 
surroundings. These simulation systems were coined as 
LCAT-water-open-AA and LCAT-water-closed-AA systems 
(see more details in the Materials and Methods).
First, the simulation trajectories were utilized to investi-
gate the conformational stability, dynamics, and secondary 
structure changes of LCAT. As it stands out from Fig. 1A, 
the lid-loop exposes the active site for the entry of lipid li-
gands in its open state and shields the active site from water 
in the closed state. The RMSD profiles in Fig. 1B (inset) 
indicate that the backbone atoms of LCAT stabilized after 
50 ns and only small deviations from the initial structures 
occurred. This was reflected by the average RMSDs of 0.14–
0.17 nm compared with the initial backbone atom scaf-
folds. By examining the mobility of LCAT as a function of 
residue number (RMSF profiles in Fig. 1B), it was found 
that the lid-loop region (amino acids 233-247) showed the 
highest conformational fluctuations compared with the 
other structural parts of LCAT when neglecting the first 
few N- and C-terminal residues. This was an expected re-
sult. Concerning the secondary structure of LCAT (Fig. 
1C), the analysis showed a stable structure without signifi-
cant changes during the simulations. A closer inspection 
revealed that the secondary structure of the lid-loop was 
random-coil-rich in both conformational states, agreeing 
with the RMSF profiles that showed a high flexibility for 
this region.
Next, we analyzed the surface properties of LCAT and 
SASAs for the hydrophobic amino acids located at the ac-
tive site tunnel opening (Fig. 2A) because we hypothesized 
that the lid-loop shields these amino acids before LCAT 
detaches from the lipoprotein surface to the water phase. 
As shown in Fig. 2B, the surface representations of LCAT as 
a function of residue types (nonpolar, polar, and charged) 
reveal that hydrophobic amino acids located at the tunnel 
opening of the active site are exposed to the water phase in 
the open state and shielded from the water in the closed 
state. This result was supported by SASA calculations (aver-
ages from the last 300 ns) indicating that four of five hydro-
phobic residues located at the active site tunnel opening 
became shielded from the water in the closed state (Fig. 
2C). More specifically, these amino acids were LEU62, 
PHE67, LEU117, and ALA118.
Considering the previous finding that hydrogen bonds 
and salt bridges play a role in the lid-loop conformational 
switching of pancreatic lipase (55), we also evaluated the 
average number of hydrogen bonds and salt bridges 
formed in the lid-closed and -open states. First, we calcu-
lated the average number of hydrogen bonds formed be-
tween the lid-loop and all LCAT amino acids. Second, we 
Fig. 2. A: Structure of LCAT showing the hydropho-
bic amino acids located at the tunnel opening of the 
active site. LCAT is rendered with a cartoon represen-
tation and the domains are colored as in Fig 1. Addi-
tionally, the lid region of LCAT is colored with blue 
(the open state) or red (the closed state). Nonpolar 
amino acids interacting with the lid-loop in the closed 
state are labeled with the corresponding residue 
names and rendered with white van der Waals spheres. 
B: The surface presentations for LCAT in the lid-open 
and lid-closed conformations. The location of the hy-
drophobic region is marked with black and dashed 
squares. Red indicates negatively charged, blue posi-
tively charged, green polar, and white hydrophobic 
amino acid residues. The salt bridges formed by the 
lid-loop are marked with arrows. C: The average SASAs 
for the selected nonpolar amino acids in the lid-open 
and -closed states. D: The average number of hydro-
gen bonds between the lid-loop and all protein resi-
dues or non-lid protein residues in the lid-open and 
-closed states. Errors bars are standard deviations.
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analyzed the average number of hydrogen bonds formed 
between the lid-loop and the non-lid-loop amino acids of 
LCAT. The results revealed that the lid-loop forms five in-
ternal hydrogen bonds when the conformational change 
from the closed to the open state takes place (Fig. 2D). 
However, the salt-bridge analysis indicated the breakage of 
two salt bridges formed by ARG244-ASP335 and ARG244-
GLU241 at the same time (Fig. 2B). Our analysis did not 
register stable salt bridges between the lid-loop and the 
non-lid-loop residues in the lid-open state. In addition, no 
internally formed lid-loop salt bridges were found in the 
open state.
The lid-open conformation enables a deeper burial of the 
tunnel-opening nonpolar amino acids of LCAT at lipid 
surfaces
In the previous section, we established that LCAT ex-
poses the nonpolar amino acids located at the tunnel open-
ing to water while the lid is open. Next, we asked whether 
these nonpolar amino acids could also interact with lipid 
bilayers resembling the lipid moiety of discoidal HDL par-
ticles. Additionally, we hypothesized that the lid-closed 
conformation also prevents the burial of the tunnel-open-
ing nonpolar amino acids to a lipid matrix, which might be 
a prerequisite for the entry of lipid ligands in addition to 
the lid-open state. Therefore, we carried out atomistic and 
CG molecular dynamics simulations of LCAT to investigate 
how these nonpolar amino acids interact with a bilayer 
composed of DOPCs and CHOL. LCAT was initially placed 
on the surface of an equilibrated bilayer in a way that en-
abled the interaction of the tunnel-opening nonpolar resi-
dues with the lipid matrix. Both the lid-closed and -open 
states of LCAT were modeled. The atomistic simulations 
(termed as LCAT-mem-open-AA and LCAT-mem-closed-
AA) enabled us to study the atom-scale interactions be-
tween LCAT and individual lipids in a microsecond time 
window. On the other hand, the CG representations 
(LCAT-mem-open-CG and LCAT-mem-closed-CG) extended 
the time window up to several microseconds, rendering it 
possible to estimate, e.g., the free-energy of binding of 
LCAT to a lipid bilayer in lid-open and -closed states utiliz-
ing umbrella sampling simulations.
Simulation trajectories revealed that LCAT stays at the 
surface of the lipid bilayer up to 1 or 20 s in atomistic and 
CG simulations, respectively (see supplemental Movies 
S1–S4). What stands out from the trajectories is that the 
nonpolar amino acids of the tunnel opening and the mem-
brane-binding region stay buried in the lipid matrix in 
LCAT-mem-open-AA and LCAT-mem-open-CG simula-
tions (Fig. 3A; supplemental Movies S1, S2). However, the 
lid-closed conformation prevents the deeper burial of tun-
nel-opening nonpolar amino acids to the lipid matrix (sup-
plemental Movies S3, S4). Closer inspection by utilizing 
distance calculations with respect to the phosphorous at-
oms of DOPCs revealed that the hydrophobic amino acids, 
L117, L64, F67, W48, L68, and L70, were clearly located in 
Fig. 3. A: Snapshots from the end of LCAT-mem-
open-AA simulation (1 s). The coloring of LCAT do-
mains is the following: orange is the / hydrolase 
domain, purple the cap domain, and red the mem-
brane-binding domain. Gray sticks represent DOPC 
molecules and green spheres phosphorous atoms of 
DOPC. Water molecules have been removed from the 
snapshots for clarity. The membrane-penetrating hy-
drophobic residues of LCAT are marked and labeled 
to the snapshots. B: The average center of mass dis-
tances from the phosphorous atoms of DOPCs for the 
lipid-buried nonpolar amino acids in the lid-open and 
lid-closed membrane simulations (left); the average 
tilt angle of LCAT with respect to the normal of lipid 
membrane in LCAT-mem-open-CG and LCAT-mem-
closed-CG simulations (right). In addition, snapshots 
approximating the average tilt angle in each case are 
shown. Coloring is the same as in A, but the tilt vector 
forming amino acids (ASN131 and MET49) has been 
marked with green spheres. C: The 2D-number den-
sity maps for UC in LCAT-mem-open-AA and LCAT-
mem-open-CG simulations. The center of mass of 
PHE67 is marked by a star showing the location of the 
membrane-penetrating region of LCAT.
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the acyl chain region of PLs in LCAT-mem-open-AA simu-
lation (see the left panel in Fig. 3B). From the distance 
analysis, we can see that these amino acids became less bur-
ied in the lipids in the lid-closed conformation, especially 
amino acids A118, L117, L64, F67, W48, L68, and L70 (see 
also supplemental Movie S3). As shown in Fig. 3B, this 
trend was also seen in CG simulations, further verifying our 
initial hypothesis that the lid configuration plays an impor-
tant role in regulating the interaction mode of LCAT with 
lipids. Further analysis revealed that the lid-closed state 
also changes the orientation of LCAT with respect to the 
lipid bilayer surface, which explains the decreased burial of 
A118, L117, and L64 located at the hydrophobic tunnel 
opening. This is shown by a higher average tilt angle of 
LCAT calculated between the vector formed by the C-
atoms of MET49 and ASN131, and the lipid bilayer normal 
(Fig. 3B; supplemental Movies S2–S4).
Next, we asked whether the tunnel opening and mem-
brane anchoring regions could interact with DOPC or UC 
molecules in a more specific way. To characterize this, we 
analyzed the 2D-number densities by first dividing the XY-
plane into 100 × 100 or 36 × 36 squares depending on the 
system studied, atomistic or CG representation, respec-
tively. This was followed by the calculation of the number 
densities of DOPC and UC atoms in each square (See more 
details in the Materials and Methods). We found no specific 
binding in the case of DOPC molecules, but UC molecules 
preferred to accumulate next to the membrane-penetrat-
ing region of LCAT in both atomistic and CG simulations 
(Fig. 3C; supplemental Fig. S2).
LCAT interaction region-derived peptides of apoA-I 
facilitate the binding of LCAT to a lipid surface
To gain additional mechanistic insights regarding the 
interactions of LCAT with lipids and the possible role of 
apoA-I in this, we studied the binding of LCAT to a lipid 
bilayer with and without apoA-I-derived peptides by em-
ploying the QCM technique. The apoA-I-derived peptides 
were selected from the previously proposed LCAT-activa-
tion region (26) and were based on the apoA-I amino acids 
of 122-142, 135-155, and 150-170 (Fig. 4A). In addition, a 
control peptide was chosen from the region of apoA-I com-
prising amino acids 185-205, which is not involved in the 
activation of LCAT. The effect of mutation Y166F on the 
properties of peptides 150-170 was also studied because it 
has been demonstrated that this mutation hampers the ac-
tivity of LCAT (56).
The QCM results in Fig. 4B indicate that LCAT binds to 
the POPC membrane without apoA-I, agreeing with previous 
experimental studies and our simulation results showing 
that LCAT stays at the lipid membrane utilizing the tunnel-
opening nonpolar amino acids or membrane-binding 
Fig. 4. A: Schematic illustration showing the peptides studied along the sequence of apoA-I. B: QCM responses for the pure LCAT (blue 
curve) and peptides (black curves) on the surface of the POPC bilayer. Surface responses of LCAT in conjunction with peptides are shown 
in red. The sum curve of pure LCAT and peptide measurements is marked as a dashed black curve. The horizontal dashed lines mark the 
minimum responses for different measurements, including their value. The result for peptide 135-155 is not shown, but the profile is similar 
to the case of peptides 150-170 (see supplementary Fig. S3). C: PMF calculations for different peptides in coil (black) or helical (red) secondary 
structure as a function of distance from the center of a lipid bilayer. The binding free-energies for the peptides (kilojoules per mole) are 
marked next to the dashed black lines.
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region in the attachment. The results also pointed out that 
some of the apoA-I-derived peptides did not interact with 
lipids, namely, only peptides 122-142, 185-205, and 150- 
170-Y166F were found to bind to the lipid bilayer (see 
Fig. 4B, solid black curve). The combined interaction stud-
ies of LCAT and peptides revealed that peptide regions 
122-142, 135-155, and 150-170 clearly increased the affinity 
of LCAT to the lipid bilayer (Fig. 4B). Results also showed 
that peptides 185-205 and 150-170-Y166F did not increase 
the lipid bilayer affinity of LCAT.
As peptides 150-170 and 135-155 did not interact with 
the lipid surface individually, but still increased the overall 
binding of LCAT, we hypothesized that the putative apoA-I 
interaction site of LCAT could induce amphipathic -helical 
structures for the peptides driving stronger lipid interac-
tion due to increased lipophilicity of the LCAT-peptide 
complexes. Another hypothesis considered the possible 
role of the peptides in changing the conformation of the 
lid from the closed to the open state, enabling a stronger 
interaction of LCAT with lipids.
To test the first hypothesis, we calculated the PMF pro-
files for each peptide when they are transferred from the 
water phase to the lipid-water interface utilizing CG simula-
tions. We carried out calculations with both coil and -helix 
secondary structures to investigate the role of the second-
ary structure of apoA-I-derived peptides regarding the 
membrane interactions. The results depicted in Fig. 4C 
indicate that all peptides can bind to the surface of the 
lipid bilayer if they adopt -helix conformation. However, 
none of the peptides showed a free-energy minimum within 
the membrane region in the coil form. Therefore, for a 
peptide region to induce stronger binding of LCAT to the 
lipid membrane surface, it must fully or partly adopt an 
amphipathic -helical secondary structure to interact with 
the unknown apoA-I interface of LCAT.
To assess the possibility of the second hypothesis, we cal-
culated the binding free-energies for LCAT in open and 
closed states. As shown by the PMF profiles in Fig. 5A, the 
lid-open state (Gwater→lipid = 28 ± 1 kJ/mol) is not able to 
bind so strongly to lipids when compared with the lid-
closed state (Gwater→lipid = 34 ± 1 kJ/mol), although the 
previous findings indicated a deeper lipid interaction for 
the open state (Fig. 3B). The value for the closed state is 
well in agreement with existing experimentally determined 
dissociation constants giving binding a free-energy value of 
36 kJ/mol for LCAT when interacting with small unila-
mellar vesicles in the absence of apolipoproteins (22).
To also elucidate the specificity of different peptide re-
gions against LCAT, we carried out MP-SPR experiments to 
determine dissociation constants (Kd) for the LCAT-pep-
tide complexes. The peptides were attached to streptavi-
din-coated gold sensors via a biotin anchor and LCAT was 
flowed over the anchored peptides to measure the Kds us-
ing a Langmuir model (see more details in the Materials 
and Methods). From the MP-SPR results (Fig. 5B, Table 2), 
it can be deduced that the three strongest affinities of 
LCAT were with peptide regions 150-170, 122-142, and 
135-155, while the lowest affinities were against peptides 
185-205 (control) and 150-170-Y166F. These results suggest 
that LCAT possesses a more specific binding site for pep-
tides 150-170, 122-142, and 135-155. This is also corrobo-
rated by the QCM results, which correlate well with the 
affinity values obtained from SPR measurements (Table 2).
The acyl-intermediate of LCAT lures CHOL molecules to 
the active site
The entry of lipids to the active site of LCAT is still mech-
anistically an unknown process (14, 26). Especially, the 
possible direct role of apolipoproteins is unknown. To gain 
additional insight into this matter, we calculated PMF pro-
files for DOPC and UC molecules when they were pulled 
from the lipid matrix to the active site of LCAT. PMF calcu-
lations were carried out utilizing the equilibrated confor-
mation of LCAT in the LCAT-mem-open-AA simulation. 
We assumed that the lid should be in the open state before 
entry of ligands.
The results in Fig. 6 indicate that the free-energy costs of 
pulling DOPC or UC molecules from the lipid matrix to 
the active site are approximately 65 ± 2 kJ/mol and 35 ± 
4 kJ/mol, respectively. The transfer free-energy cost of 
DOPC matched well with the experimental LCAT activation 
Fig. 5. A: PMF profiles for LCAT as a function of distance from 
the center of the lipid bilayer. The transfer free-energies of LCAT 
from water to the lipid bilayer surface are marked next to the 
dashed lines (kilojoules per mole). B: Surface plasmon resonance 
peak responses for different apoA-I-derived peptides as a function 
of LCAT concentration.
TABLE 2. MP-SPR derived dissociation constants (Kd) and Rmax values for different LCAT-peptide complexes
Peptide Kd (M) Rmax QCM Difference
a
122-142 1.0258 139.1 0.5
135-155 0.8193 301.0 1.0
150-170 0.2903 25.4 0.9
150-170-Y177F 1.8442 174.4 0
185-205 4.6901 103.4 0.3
a The QCM response differences between the combined LCAT+peptide and the sum of separate (LCAT and 
peptide alone) measurements are given.
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energies that ranged from 53 to 76 kJ/mol measured for 
HDL-LCAT complexes comprised of POPC or DOPC lipids 
(57, 58). Next, we asked whether the acylation of SER181 
decreases the free-energy cost needed for UC to enter the 
active site. Thus, we constructed an atomistic simulation 
system where SER181 was acylated and the lid was in the 
open state (LCAT-mem-acyl-AA). Surprisingly, we found 
that the acyl-intermediate of LCAT did not only decrease 
the free-energy cost, but rendered the entry of UC to the 
active site almost favorable, reflected by the transfer free-
energy value of 4–7 kJ/mol (Fig. 6A). To investigate the 
dynamics of this process further, we carried out a CG simu-
lation with acylated SER181 (LCAT-mem-acyl-CG). The 
simulation trajectory revealed that after approximately 
1.6 s (scaled MARTINI time, see Table 1) a CHOL mol-
ecule spontaneously diffused to the active site (Fig. 6C, 
supplemental Movie S5), agreeing with our free-energy cal-
culations. This was also registered by calculating the con-
tacts between the side chain atoms of SER181 and the 
hydroxyl group of UC molecules (see Fig. 6B). In addition, 
a closer inspection unveiled that the exchange of CHOL 
molecules between the active site of LCAT and the lipid 
membrane can occur if the esterification reaction does not 
take place (supplemental Movie S6).
DISCUSSION
In the present study, we have studied the interactions of 
LCAT with lipid surfaces and apoA-I-derived peptides to 
gain novel information regarding the molecular mecha-
nism behind the LCAT-catalyzed CHOL esterification tak-
ing place at the surface of lipoprotein particles. To achieve 
this, we employed extensive atomistic and CG molecular 
dynamics simulations, as well as experimental surface-sensi-
tive biophysical methods.
The simulation results showed that the lid region of 
LCAT forms a coil secondary structure accompanied by 
relatively high residual fluctuations when compared with 
the other structural parts of LCAT. The fact that the lid 
regions are partly missing from the X-ray structures of LCAT 
agrees with our simulation results showing a highly mobile 
region with no definite structural conformation (32–34). 
Another important finding was that the highly dynamic 
lid-loop shields the nonpolar amino acids located at the 
tunnel opening from the water. Moreover, we suggest that 
when the lid-loop undergoes the conformational change 
from the closed to the open state, two salt bridges are bro-
ken and four intra-lid hydrogen bonds are formed. These 
findings support the view that the lid functions as a dy-
namic gate regulating the access of PLs and CHOL mole-
cules into the active site. In general, lipases are known to 
possess open and closed states (35, 59, 60). For example, 
the X-ray structures of pancreatic lipase indicate that the 
opening of the active site is accompanied by considerable 
structural changes of the lid region governed by nonpolar 
contacts, hydrogen bonds, and salt bridges (61). Although 
we have studied a structurally different enzyme, these find-
ings are consistent with our results. Based on the current 
findings, it is tempting to speculate that the closed state of 
LCAT is stabilized in water by the lid-mediated shielding of 
the nonpolar amino acids at the active site tunnel opening 
and the presence of two salt bridges. It is possible, there-
fore, that the entropic cost associated with conformational 
switching from the closed to the open state in water mainly 
arises from exposing the lid-covered nonpolar amino acids 
to aqueous surroundings. After LCAT becomes bound to 
lipoprotein particles, presumably this entropic cost de-
creases because the nonpolar residues at the tunnel open-
ing may become buried in a hydrophobic lipid matrix, as 
shown by our atomistic and CG simulations. Thus, it is pos-
sible to hypothesize that this could be one of the reasons 
why the lid-open state could be favored when LCAT is 
bound to lipoprotein particles. Yet, CG simulations re-
vealed that LCAT can strongly interact with lipids, even in 
the lid-closed state, which was accompanied by a greater 
distance between the / hydrolase domain and the lipid 
bilayer surface. This conformation does not allow the 
burial of the tunnel-opening nonpolar amino acids in lip-
ids, which we propose to be a prerequisite for the entry of 
lipids to the active site.
Interestingly, according to our simulations, UC mole-
cules prefer to accumulate next to the membrane-penetrat-
ing region of LCAT. This finding may be due to packing 
defects between LCAT and PLs. The tendency of UC mol-
ecules to concentrate adjacent to the tunnel-opening non-
polar amino acids indicates its important role in regulating 
the accessibility of UC molecules into the active site over 
Fig. 6. A: PMF profiles for DOPC and UC calculated 
in a LCAT-mem-open-AA system. In addition, the PMF 
profile for UC in a LCAT-mem-acyl-AA system is shown. 
B: The number of contacts between the oleate chain 
beads linked to SER181 and CHOL beads as a func-
tion of time. C: Snapshot from a LCAT-mem-acyl-CG 
simulation showing the location of the UC molecules 
in the active site of LCAT. CHOL molecules are ren-
dered as orange spheres, DOPC molecules as gray 
sticks, the phosphate beads of DOPC as green spheres, 
LCAT backbone atoms as red sticks, the oleate chain 
beads linked to SER181 as cyan spheres, and SER181 
as violet spheres.
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PLs. This could be one of the reasons why LCAT is the sole 
enzyme among lipases catalyzing the esterification of UC 
molecules. This issue can be further clarified by examining 
the lipid surface interaction of other lipases.
Our QCM measurements revealed that the peptides 
derived from the LCAT-interaction region of apoA-I in-
creased the binding of LCAT to lipid surfaces, while the 
control peptides 185-205 and the mutant peptides 150- 
170-Y166F did not facilitate the LCAT interaction with 
lipids. These findings agree with previous experimental re-
ports showing that apoA-I increases the binding of LCAT 
to lipids compared with apolipoprotein-free small unila-
mellar vesicles (14, 22). Earlier it has been shown that the 
apoA-I mutation, Y166F, decreases the surface binding and 
activity of LCAT, which is in agreement with our experi-
mental results (56, 62). In general, many studies have 
pointed out that the charged and polar amino acids lo-
cated in the central parts of apoA-I are important in LCAT 
activity (26, 31). One of our unanticipated findings was 
that, although some of the peptides did not interact with 
lipids alone, they still contributed strongly to the lipid at-
tachment of LCAT. Namely, peptides 135-155 and 150-170 
did not interact with lipids at all, and peptides 122-142 
showed only a modest interfacial activity. Nevertheless, 
these peptides greatly increased the binding of LCAT to 
lipid surfaces when compared with the more surface-active 
peptides 150-170-Y166F and 185-205. Interestingly, the 
computational free-energy calculations revealed that all 
the peptides studied must adopt fully or partially amphipa-
thic -helical conformations before they can interact with 
lipid surfaces. It can thus be suggested that the LCAT-acti-
vating central region of apoA-I may adopt water-exposed 
loop conformations before interacting with LCAT. The in-
teraction of loop structures with LCAT could be followed 
by a conformational change from the coil to -helix lead-
ing to stronger binding of LCAT to HDL particles. The 
MP-SPR results support this view because it was shown that 
the apoA-I-derived peptides can bind to LCAT without the 
presence of a lipid surface. Further, based on the free- 
energy calculations of LCAT, it is evident that apoA-I-derived 
peptides do not increase the binding of LCAT-peptide 
complexes to lipid surfaces by merely changing the lid 
from closed to the open state because the lipid binding 
free-energy for the open state of LCAT was lower compared 
with the closed state. Overall, these findings strengthen the 
results shown in the previous experimental studies demon-
strating that the central region of apoA-I possesses much 
lower -helical stabilities and, thus, an increased tendency 
to form looped structures compared with other regions 
(56, 63, 64).
The free-energy calculations produced in the present 
study support the view that the entry of lipids into the ac-
tive site of LCAT likely occurs without the direct involve-
ment of apoA-I. One major finding supporting this view 
was that the calculated transfer free-energy of DOPC from 
the lipid bilayer into the active site (65 kJ/mol) is congru-
ent with the experimentally determined activation ener-
gies of LCAT in reconstituted HDL particles with varying 
PL species (53–76 kJ/mol) (57, 58). This result is also 
consistent with the data demonstrating that the apolipo-
protein content of HDL particles does not affect the activa-
tion energy of LCAT (65). The second major finding was 
that the acylation of SER181 renders the transfer free-en-
ergy of CHOL much lower when compared with the nonac-
ylated case (4–7 kJ/mol vs. 35 kJ/mol). With respect to this 
finding, we observed that UC molecules spontaneously dif-
fused into the active site in CG simulations when SER181 
was acylated. The CG-simulations further revealed that the 
exchange of UC molecules in the active site took place in 
20 s. Thus, the atomistic free-energy calculations and CG 
simulations showed that the diffusion of lipids, especially in 
the case of UC molecules, to the active site of LCAT is not 
directly assisted by apoA-I. Interestingly, a recent research 
study revealed that molecular agents targeted for the lipid 
binding site of LCAT can increase the Vmax of LCAT (66). 
Surprisingly, the compound also activated LCAT deficiency 
causing mutants, which raises hopes for treating these dis-
orders in the future. It was identified with molecular mod-
eling that the LCAT-activating compound A formed a 
hydrophobic adduct with CYS31 located in the active site. 
Thus, one reason for the higher LCAT activity could be 
that the compound A renders the active site of LCAT ener-
getically more favorable to PLs to diffuse in. In other words, 
the drug lowers the activation energy of LCAT, which is 
essentially covered by the transfer of a PL from the lipid 
monolayer to the active site.
To conclude, our results suggest that the initial bind-
ing of LCAT to the lipoprotein surface occurs with the 
help of nonpolar amino acids in the membrane-binding 
domain. The initial lipid interaction of LCAT is likely 
followed by an as yet unknown interaction with apoA-I, 
which enables the opening of the lid and the conforma-
tional change of LCAT to the configuration where the 
tunnel-opening nonpolar amino acids become buried in 
lipids. In addition, free CHOL molecules are attracted 
adjacent to the tunnel opening. Meanwhile, amino acids 
135-170 of apoA-I increase the binding of LCAT to lipo-
proteins. Thus, apoA-I enables the diffusion of PLs to the 
active site via conformational and structural changes, 
which leads to the formation of the acyl-intermediate of 
LCAT. This, in turn, greatly facilitates the diffusion of UC 
molecules to the active site without the direct involve-
ment of apoA-I. The evidence from this study suggests 
that the role of apoA-I and other apolipoproteins in acti-
vating LCAT is to adjust the conformation of LCAT with 
respect to the lipid surface, increase the binding of 
LCAT, and drive the lid to the open state. The reasons for 
varying LCAT activation potencies of different apolipo-
proteins could be speculated to arise from their different 
capacity to control these features (57). What is highly 
surprising is that the apoA-I-derived peptides can in-
crease LCAT binding to lipids, even if some of them do 
not interact with lipids individually. These findings en-
courage further investigations and modifications of these 
peptides aiming to increase the activity of LCAT.
It should be noted that our simulated LCAT models do 
not include the amino acids 1-20 and 398-422 of the N- and 
C-terminal ends, respectively. This was because of the high 
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uncertainties associated with these parts based on the 
published X-ray structures. Further, according to the hy-
drogen-deuterium exchange measurements carried out 
by Manthei et al. (33), these structural regions of LCAT 
are highly dynamic and solvent exposed, which renders 
their structure even more difficult to assess. Earlier it was 
shown by Vickaryous et al. (67) that the first few N-termi-
nal amino acids are important for the activity of LCAT. In 
the same study, it was shown that the HDL and LDL bind-
ing was unaffected by the N-terminal deletion mutants of 
LCAT (1 and 2). Recently however, during the prepa-
ration of our article, a report was published that the dele-
tion of amino acids 1-20 and 398-422, as well as the point 
mutations W48A and L70S, decreased the binding of 
LCAT to the HDL particles with apoA-I or mimetic pep-
tides the most (33). The highly decreased binding of 
W48A and L70S mutants to HDL particles is in good ac-
cordance with our simulation results showing that resi-
dues W48 and L70 interact with lipids and stay buried in 
the lipid acyl chain region in the lid-open state. In addi-
tion to the lipid-interacting hydrophobic amino acids re-
ported here, it is also possible that the N- and C-terminal 
parts can interact with lipids, apoA-I, or both and further 
enhance LCAT binding to the surface of HDL particles. 
It is also plausible that the membrane-binding domain 
together with the N- and C-terminal ends interact with 
the molecular components of HDL in a manner that 
adjusts the active site tunnel opening closer to lipids, 
enabling lipid entry after the lid is in the open state. 
Nonetheless, our free-energy calculations show that the 
binding of LCAT to the lipid bilayer in its closed-lid state 
is well in agreement with the experimentally detected 
binding free-energy for LCAT binding to small unilamel-
lar vesicles without the presence of apolipoproteins (34 
kJ/mol vs. 36 kJ/mol, respectively) (22). Based on this 
information, it is tempting to hypothesize that the N- and 
C-terminal ends are mainly responsible for the interac-
tion with apoA-I and other apolipoproteins after the ini-
tial attachment of LCAT to the lipid moiety of HDL 
particles via the membrane-binding domain.
Another limitation of our study is that we have only stud-
ied LCAT on planar lipid surfaces (mimicking discoidal-
HDL particle surfaces). As a result, we do not understand 
the effect and magnitude of lipoprotein particle curvature, 
size, and type on our results; although it has been shown 
that these features modulate the activity of LCAT (68).
Our study provides a novel framework for the explora-
tion of LCAT activation by apolipoproteins, apolipoprotein 
mimetic peptides, and other pharmacological compounds. 
Eventually, the approaches presented in this study may 
lead to the development of more advanced apolipoprotein 
mimetic peptides that could be used in the treatment of 
different metabolic disorders, such as dyslipidemia and 
LCAT deficiencies (69, 70). However, the beneficence of 
pharmacological compounds aiming to promote the activ-
ity of LCAT in the treatment of CHD is still under debate. 
Therefore, further investigations are needed to clarify the 
role of LCAT in the development of CHD before pharma-
cological interventions.
The authors acknowledge the CSC-IT Centre for Science Ltd. 
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